← Back to Home

Keytruda’s high tumor mutational burden indication gains traditional approval as FDA raises treatment threshold

The increase from 10 to 13 mutations per megabase also redefines treatment eligibility. Efficacy in the lower range was not confirmed, clarifying the boundaries of this tumor-agnostic immunotherapy indication.

By SURL BioNews

A number on a tumor genomic testing report may change whether a patient qualifies for immunotherapy. The US Food and Drug Administration (FDA) has converted Keytruda’s indication for tumor mutational burden-high (TMB-H) solid tumors to traditional approval while raising the threshold from at least 10 to at least 13 mutations per megabase. Patients whose results fall between 10 and less than 13, who previously qualified under this indication, are no longer covered.

The FDA announced the decision on October 22, 2026, with an actual approval date of October 16. Oncology Nursing News reported that the approval covers intravenous Keytruda (pembrolizumab) and subcutaneous Keytruda Qlex. The indication remains for unresectable or metastatic TMB-H solid tumors that have progressed following prior treatment and for which there are no satisfactory alternative treatment options; the mutational burden must be confirmed by an FDA-approved test.

A distinctive feature of this indication is that it selects patients across cancer types based on their tumors’ molecular characteristics. TMB measures the number of mutations per megabase, but the threshold for “high” is not fixed. The FDA explained that efficacy in patients with TMB between 10 and less than 13 could not be confirmed to the standard required for traditional approval. It therefore narrowed the eligible population as it completed the conversion.

The data supporting this approval came from the phase 2 KEYNOTE-158 trial, combining a prospectively enrolled population with retrospective analyses of multiple existing cohorts. Among 220 patients who met the new threshold and received at least one dose of pembrolizumab, the objective response rate was 36%, meaning that approximately one-third of patients had tumor shrinkage that met the trial’s specified criteria. This figure describes tumor response and cannot be directly interpreted as the magnitude of any survival extension.

There were already signs of a difference between the two mutational burden ranges at the time of the initial approval. In its summary of the analysis from that time, Oncology Nursing News noted that the objective response rate was 37% among 70 patients with TMB of at least 13, compared with 13% among 32 patients with TMB between 10 and less than 13. However, these were small subgroup datasets and do not establish that every patient in the lower range would fail to benefit.

The FDA’s approval conversion records show that this indication initially received accelerated approval on June 16, 2020, using a threshold of at least 10 mutations per megabase. Its conversion to traditional approval reflects subsequent evidence supporting the treatment’s value in the population with higher mutational burden, while the original, broader eligibility definition has been adjusted in line with the evidence. The FDA’s table still lists the original accelerated approval criteria, which must be distinguished from this update when reading it.

The new evidence also has limits. The efficacy data came from single-arm cohorts and cannot provide a direct comparison with other treatments; the announcement also did not report overall survival, progression-free survival, or responses by individual cancer type in the updated population. For precision oncology, this change reinforces a continuing point: testing can help guide treatment selection, but biomarker labels and thresholds must continue to be tested against clinical outcomes.

References

  1. FDA
  2. Oncology Nursing News
  3. FDA